Decade after first approval, bispecifics on the precipice of going mainstream

Part 2 of an interview with AstraZeneca’s head of oncology

Global biotech sees Brukinsa and pipeline as growth engines as it relies on ‘CRO-free’ R&D model, protects supply chain

Lilly’s dual GLP-1R/GIP agonist shows early efficacy in MASH; Blenrep combo beats Darzalex combo in MM

‘No change’ to strategy of seeking bolt-ons worth $5B or less, suggesting Cytokinetics takeout is unlikely

BioCentury’s roundup of translational innovations

The majority of T cell checkpoint targets tracked by BioCentury continue to see new entrants to the pipeline

GSK’s TIM3 inhibitor cobolimab moves to Phase III; PD-1 mAb shows non-inferiority to Keytruda

Snapshots from the literature add to the growing picture of next-gen CAR T manipulations that could enhance multiple cancer therapies